Study
|
Year
|
Country
|
Duration
|
Histology
|
Sample size (Femal/Male)
|
Age
|
Treatment
|
Sampling time
|
NLR Cut-off value
|
Outcome
|
NOS score
|
---|
Bambury et al. [17]
|
2013
|
USA
|
2004-2013
|
glioblastoma multiforme
|
84 (19/65)
|
median 58
|
S+R+C
|
pretreatment
|
4
|
multivariate
|
7
|
Han et al. [18]
|
2015
|
China
|
2010-2014
|
glioblastoma
|
152 (57/95)
|
mean 50
|
NR
|
pretreatment
|
4
|
multivariate
|
6
|
Auezova et al. [19]
|
2016
|
Russia
|
2009-2012
|
gliomas
|
178 (85/93)
|
mean 41
|
NR
|
pretreatment
|
4
|
univariate
|
5
|
S.S.Q. et al. [29]
|
2017
|
Singapore
|
NR
|
glioblastoma
|
58 (NR)
|
NR
|
NR
|
perioperative
|
2.5
|
multivariate
|
5
|
Kaya et al. [20]
|
2017
|
Turkey
|
2011-2015
|
glioblastoma
|
90 (NR)
|
mean 55
|
S+R+C
|
pretreatment
|
5
|
multivariate
|
5
|
Lopes et al. [21]
|
2017
|
Portugal
|
2005-2013
|
glioblastoma multiforme
|
140 (42/98)
|
mean 62
|
S+C
|
pretreatment
|
5
|
multivariate
|
5
|
Matthew et al. [22]
|
2017
|
Canada
|
2004-2010
|
glioblastoma
|
369 (131/238)
|
median 55
|
S+R+C
|
postoperative
|
7.5
|
multivariate
|
5
|
Wang et al. [23]
|
2017
|
China
|
2009-2014
|
glioblastoma
|
166 (70/96)
|
mean 52
|
NR
|
pretreatment
|
4
|
multivariate
|
5
|
Wiencke et al. [24]
|
2017
|
USA
|
NR
|
glioma (grade II-IV)
|
72 (20/52)
|
median 47
|
NR
|
postoperative
|
4
|
multivariate
|
5
|
Bao et al. [28]
|
2018
|
China
|
2012-2017
|
glioma
|
219 (95/124)
|
NR
|
NR
|
pretreatment
|
2.5
|
multivariate
|
6
|
Wang et al. [25]
|
2018
|
China
|
2010-2013
|
glioma (grade I-IV)
|
112 (42/70)
|
mean 50
|
NR
|
pretreatment
|
4
|
multivariate
|
6
|
Weng et al. [26]
|
2018
|
China
|
2011-2014
|
glioblastoma
|
105 (52/53)
|
NR
|
S+R+C
|
pretreatment
|
4
|
multivariate
|
5
|
Yersal et al. [27]
|
2018
|
Turkey
|
2012-2017
|
glioblastoma
|
80 (41/39)
|
mean 56
|
S+R+C
|
pretreatment
|
4
|
univariate
|
5
|
Hao et al. [31]
|
2019
|
China
|
2012-2017
|
glioblastoma multiforme
|
187 (71/116)
|
mean 55
|
NR
|
NR
|
4.1
|
univariate
|
6
|
Yang et al. [30]
|
2019
|
China
|
2008-2012
|
glioblastoma multiforme
|
128 (57/71)
|
mean 55
|
S+R+C
|
NR
|
2.8
|
multivariate
|
5
|
Gan et al. [32]
|
2019
|
China
|
2014-2018
|
glioma (grade III-IV )
|
135 (46/89)
|
Mean70
|
S+R+C
|
pretreatment
|
3
|
multivariate
|
5
|
- NR Not reported, S Surgery, R Radioation, C Chemotherapy, NOS Newcastle Ottawa Scale